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High‐resolution mass spectrometry (HRMS) is an important technology for studying
biotransformations of drugs in biological systems. In order to process complex HRMS
data, bioinformatics, including data‐mining techniques for identifying drug metabo-
lites from liquid chromatography/high‐resolution mass spectrometry (LC/HRMS) or
multistage mass spectrometry (MSn) datasets as well as elucidating the detected
metabolites’ structure by spectral interpretation software, are important tools.
Data‐mining technologies have widely been used in drug metabolite identification,
including mass defect filters, product ion filters, neutral‐loss filters, control sample
comparisons and extracted ion chromatographic analysis. However, the metabolites
identified by current different technologies are not the same, indicating the impor-
tance of technique integration for efficient and complete identification of metabolic
products. In this study, a universal, high‐throughput workflow for identifying and ver-
ifying metabolites by applying the drug metabolite identification software UNIFI is
reported, to study the biotransformation of verapamil in rats. A total of 71 verapamil
metabolites were found in rat plasma, urine and faeces, including two metabolites
that have not been reported in the literature. Phase I metabolites of verapamil were
identified as N‐demethylation, O‐demethylation, N‐dealkylation and oxidation and
dehydrogenation metabolites; phase II metabolites were mainly glucuronidation and
sulfate conjugates, indicating that UNIFI software could be effective and valuable in
identifying drug metabolites.
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Drug metabolism research spans the entire drug development process.
Rapid, accurate and complete identification of drug metabolites in bio-
logical systems can improve the understanding of drugs or candidate
compounds’ biotransformation pathways, which might also facilitate
the determination of metabolic ‘soft sites’. This information is valuable
for optimizing the structure of lead compounds, selecting drugs with
high metabolic stability and exploring the drugs’ possiblewileyonlinelibrary.copharmacological or toxicological mechanisms. High‐performance liquid
chromatography–high‐resolution mass spectrometry (HPLC–HRMS)
(Song, Jin, Du, Cao, & Xu, 2016) has high resolution, accuracy and sen-
sitivity, is fast scanning and involves multistage mass spectrometry
(MSn). It is a powerful tool for analysing drug metabolites and can be
used to obtain HRMS and MSn data from potential metabolic products
in biological samples using a simple, universal collection method. How-
ever, the mass spectrometry data collected by the device contains a
large amount of data relating to endogenous compounds. Therefore,© 2019 John Wiley & Sons, Ltd.m/journal/bmc 1 of 11
2 of 11 ZHU ET AL.approaches to efficiently and comprehensively identify the information
of interest as well as to analyse metabolic products in post‐processing,
have become one of the key issues in HPLC–HRMS applications. (Gao,
Wu, & Feng, 2019; Martano, Mugoni, Dal Bello, Santoro, & Medana,
2015; Scheidweiler, Jarvis, & Huestis, 2015; Song et al., 2016)
In recent years, there have been numerous studies of post‐
processing techniques for high‐resolution mass spectrometry, and
the reported techniques can be divided into three main types. The first
is detection based on known or predictable metabolic pathways, such
as the conventional metabolic products formed by hydroxylation and
N‐dealkylation. Since the molecular weights of these products can be
predicted, high‐resolution extracted ion chromatography (HR–EIC)
can be used for targeted analysis of expected metabolite ions (Xing,
Zang, Zhang, & Zhu, 2015), thereby making detection relatively simple.
The second is post‐processing techniques based on HRMS data,
including mass defect filters (MDF) (Geng et al., 2016; Ruan & Zhu,
2010; Shang et al., 2017; Tian et al., 2015; Zhang, Zhang, Ray, &
Zhu, 2009; Zhang, Zhu, Ray, Ma, & Zhang, 2008; Zhu et al., 2006), iso-
tope pattern filters and background subtraction (BS) (Chen et al.,
2016; Wu et al., 2016; Zeng, Duan, Chen, Li, & Liu, 2017; Zhang,
Gan, Shu, & Humphreys, 2015). The third is post‐processing tech-
niques based on MSn data, including product ion filters (Cuyckens,
Hurkmans, Castro‐Perez, Leclercq, & Mortishire‐Smith, 2009; Ma,
Wen, Ruan, & Zhu, 2008; Ruan et al., 2008; Zhang & Yang, 2008),
neutral‐loss filters (NLF) (Liu et al., 2014; Ruan et al., 2008; Yao
et al., 2017) and mass spectral tree similarity filter technique (Jin,
Wu, Zhang, & Li, 2013; Vaniya & Fiehn, 2015; Wang, Wu, Qin, &
Zhang, 2014). All of these techniques address the issue of identifica-
tion or verification of metabolic products. However, current reports
show that the metabolites identified by different apporaches are not
the same, indicating the importance of technology integration for effi-
cient and complete identification of metabolic products.
In this report, we describe a strategy for a universal, high‐
throughput workflow for identifying and verifying metabolic products.
In detail, ultra‐performance liquid chromatography–tandem mass
spectrometry (UPLC–MSE) was used to collect mass spectrometry
information about verapamil compounds’ metabolites, while the UNIFI
software platform was used for data processing. This combination of
UPLC–MSE data acquisition technology and the integrated data‐
processing functions of the UNIFI platform was proved to rapidly
detect small metabolites from dealkylation, to allow direct binary com-
parison for easy metabolite identification and even to enable the
exploration of unknown metabolites, which might be suitable for
high‐throughput screening and analysis of reactive metabolites or
metabolic soft‐spots in future drug discovery.2 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
Verapamil (98%, MB1346) was purchased from the National Institute
for the Control of Pharmaceutical and Biological Products (NICPBP),methanol and acetonitrile of LC/MS grade were purchased from
Fisher Scientific (Waltham, MA, USA) and analytical grade formic acid
(99%) was obtained from Sigma‐Aldrich (USA). Purified water used in
the study was produced by a Milli‐Q integral water purification system
(Millipore Direct‐Q UV, Bedford, MA, USA).2.2 | Animals
Three male Wistar rats, weighing 220 ± 20 g, were obtained from the
Shanghai Laboratory Animal Company (Shang Hai, China). All rats
were housed under standard conditions (12 h dark–light cycle; tem-
perature 25 ± 2°C; humidity 50–75%) with access to food and water.
They were fasted for 12 h with free access to water before the
experiment.2.3 | Drug administration and biological sample
preparation
Verapamil was dissolved in saline solution. The rats were given an oral
dose of 30mg/kg body weight. After the oral administration of verap-
amil, blood samples (0.5ml) were taken from the suborbital venous
plexus of rats at 0.25, 0.75, 1.5, 3, 6, 10 and 12 h. Each sample was
centrifuged at 4000 rpm for 10min to obtain plasma samples. Urine
and faeces samples were collected 0–10 and 10–24 h after oral
administration. Control plasma, urine and faeces samples were col-
lected before administration. All samples were stored at −80°C before
analysis.
The plasma samples (0.5mL) were placed in 5mL centrifuge tubes,
and 2mL methanol was added to precipitate protein. The urine sam-
ples (1mL) were transferred to 10mL capped centrifuge tubes and
4mL methanol was added. After mixing for 30 s, the sample tubes
were centrifuged at 4500 rpm for 10min, and then the supernatants
of all plasma samples and 1mL of supernatant from each urine sample
were transferred into a new 10mL polypropylene centrifuge tube and
evaporated to dryness using nitrogen at 37°C. Finally, the plasma and
urine residues were re‐dissolved with 100 and 200 μL acetonitrile–
water (30:70, v/v) respectively, and ultrasonicated for 2min, before
being centrifuged at 12,000 rpm for 10min. The plasma supernatant
was directly injected into the LC–MS system, and the urine superna-
tant was diluted 1:10 before analysis.
The faeces samples (0.2 g) were transferred to 10mL centrifuge
tubes and mixed with 400 μL of water, followed by the addition of
800 μL of methanol solution, ultrasonicated for 15min and subse-
quently centrifuged at 12,000 rpm for 10min to obtain the superna-
tant. The supernatant was removed and dried. The residue was
reconstituted in methanol (50 μL) and diluted 1:10 and then injected
into the system for analysis.2.4 | Instruments and conditions
The chromatographic equipment consisted of a UPLC system (Waters
Acquity UPLC I‐Class). Separations were carried out on an Acquity
ZHU ET AL. 3 of 11UPL HSS T3 Column (2.1 × 100mm, 1.8 μm) maintained at 35°C. A
0.1% FA aqueous solution (solvent A) and 0.1% FA acetonitrile (sol-
vent B) were used as the mobile phases. The flow rate was set at
0.3mL/min with a linear gradient as follows: 0–0.2min, 5–5% B;
0.2–3min, 5–15% B; 3–8min, 15–24% B; 8–16min, 24–38% B; 16–
20min, 38–95% B; 20–22min, 95% B; 22–24min, 95–5% B. The
injection volumes of rat plasma, urine and faeces were 0.5, 0.1 and
0.2 μL, respectively.
Mass spectrometry was performed on a Waters Xevo G2‐XS
QTOF, equipped with an electrospray ionization source in both posi-
tive and negative ion modes. Acquisition mode was MSE; capillary
voltage, 3.0 kV; source offset, 80; sampling cone, 40.0; desolvation
temperature, 500°C; source temperature, 150°C; desolvation gas flow,
850 L/h; cone gas flow, 50 L/h; and acquisition time, 24min. Data was
acquired using MSE, and the mass was corrected using an external ref-
erence (Lock‐Spray).2.5 | Data processing
Data were processed using UNIFI (1.8.2) software. The UNIFI core is
an information library that allows researchers to map and navigate
their metabolite identification data using novel visualizations, as well
as in tabular or combined views. The data‐processing workflow is
shown in Figure 1. First, the Binary Compare function was applied to
identify potential metabolites that were not present or were present
at low ion intensities in the corresponding control samples. The rela-
tive intensity threshold was set at 3 or 5, and metabolites meeting this
requirement could be screened out. EIC was then used to find com-
mon, predictable metabolites. The characteristic fragment ions of
verapamil metabolites were m/z 303.2072, 260.1657 and 165.0917.
Therefore, compounds with m/z 303.2072, 260.1657 or 165.0917
were probably verapamil metabolites. MDF, product ion filters and
NLF were applied to detect unpredictable metabolites. MDF incorpo-
rating an intelligent dealkylation function is capable of rapidly detect-
ing small metabolites from dealkylation, with no false negative results.
The NLF function was applied to search for two‐phase metabolites.FIGURE 1 Shows the workflow of extracts
identification processFor instance, we could search for possible glucuronic acid conjugates
by setting a parameter at 176.0321 in the UNIFI software. In UNIFI,
neutral loss can be set in the method or identified after processing.
Finally, the detected metabolites’ structures were determined or char-
acterized using MassFragment, which is part of UNIFI's spectral inter-
pretation function. This is the main function used to automatically
perform secondary fragmentation analysis of parent drugs and metab-
olites. Using this function, researchers can quickly verify whether the
fragmentation path is reasonable.3 | RESULTS AND DISCUSSION
3.1 | UPLC–MSE analysis of metabolites
In this study, verapamil's metabolic profile was studied using UPLC–
MSE with the UNIFI platform, while the number of detected com-
pounds was compared with BS, MDF and MDF+ dealkylation (shown
in Figure 2). After being processed by BS, MDF and MDF +
dealkylation and UNIFI, the numbers of verapamil metabolites
screened in rat plasma were 9529, 225, 934 and 341 compounds
(shown in Supporting Table S1–S12) respectively from the total data-
base (14,283 compounds), while most of them were false positive
compounds. Only 37 true compounds were obtained after BS treat-
ment, accounting for 0.39% of the total. Some 6.67% (21 compounds)
and 2.25% (37 compounds) positive compounds after processing by
MDF and MDF+ dealkylation were screened, respectively. In short,
93% of screened compounds were false positive compounds. As
screening efficiency was poor, a large number of manual operations
were required. However, the UNIFI platform automatically screened
341 compounds from the verapamil plasma database (14,283 com-
pounds), of which 37 (accounting for 10.85%) were true verapamil
metabolites. Compared with the other three methods, UNIFI technol-
ogy showed great screening effect. Furthermore, the verapamil
metabolites in urine and faeces were also processed using BS, MDF,
MDF + dealkylation and UNIFI. The experimental results revealed that
32 (accounting for 6.43%), 12 (accounting for 27.91%), 19 (accounting
FIGURE 2 Comparison of the number of
compounds detected in the plasma using each
data processing method. The solid fills (wine
and green) indicate the total number of
compounds detected, and the green fills
indicate the number of true compounds
detected, accounting for 0.26, 0.39, 6.67, 2.25
and 10.85% of the total, respectively
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screened compounds 498, 43, 315 and 159) were obtained, respec-
tively, in urine. By calculation, the effective rates of compounds
screened from faeces were 7.69, 14.43, 6.05 and 17.49% using each
data processing method (total screened compounds 598,194, 727
and 263), respectively. It reveals that UNIFI could effectively reduce
the false positive rate, with false rates of only 89.15, 79.87 and
82.51% in plasma, urine and faeces, in comparison with the other
three methods with most of screened false rates above 92% (shown
in Supporting Figure S1).
The metabolites identified by UNIFI are summarized in Table 1,
showing the data from parent compounds and drug metabolites. A
total of 71 verapamil metabolites were found in rat plasma, urine
and faeces. The major metabolic pathways in rats are N‐ and O‐
demethylation and N‐dealkylation. Two of the detected metabolites
had not been reported in the literature. In detail, 37, 31 and 45 metab-
olites were found in plasma, urine and faeces, respectively, but only
nine metabolites (M4‐1, M4‐2, M4‐3, M5‐3, M5‐6, M7, M11‐3,
M11‐5 and M12‐5) were detected simultaneously in three substrates.
According to the reported literature, in vivo verapamil metabolism
could be affected by a number of enzymes. For example, CYP3A4,
CYP3A4 and CYP1A2 were reported to be the main enzymes respon-
sible for verapamil N‐dealkylation and CYP2C isoenzymes (particularly
CYP2C9) were mainly involved in verapamil O‐demethylation (Busse,
Cosme, Kroemer, & Eichelbaum, 1995; Sun, Zhang, & Zhong, 2004).
The enzymes responsible for the three main initial pathways of verap-
amil metabolism were identified. N‐Dealkylated metabolites were the
main metabolites in plasma and urine, while N‐ and O‐demethylated
compounds were the main metabolites in faeces (Reder‐Hilz et al.,
2004). Verapamil and its N‐dealkylated metabolites might be further
metabolized by O‐demethylation (Sun et al., 2004). In short, significant
differences in the types and amounts of metabolites detected from
the three matrices may be due to differences in the metabolic main
enzymes affecting verapamil metabolism in different matrices.3.2 | Identification of metabolite M12‐5
Most of the metabolites had similar structures. The verapamil structure
and fragment ions are shown in Figure 3. Verapamil had the theoretical
[M + H]+ ion at m/z 455.2910 (C27H38N2O4, error 0 mDa) in positive
ion mode, which eluted at 15.01min. Its fragment ions were also
obtained at m/z 303.2072, 260.1657, 165.0917 and 150.0672. There-
fore, it could be inferred that the ions at m/z 303.2072, 260.1657,
165.0917 and 150.0672 were characteristic product ions of verapamil
(M0). In order to identify metabolites, these ions were used for struc-
tural elucidation of metabolites with similar skeletons. For example,
M12‐5 belonged to a verapamil metabolite and had a retention time
of 14.66min. A base peak ion at m/z 441.2748 (C26H36N2O4,
error − 0.4 mDa) was observed. There were also fragment ions at m/z
289.1912, 260.1648, 165.0909 and 150.0672. Fragment ions at m/z
260.1648, 165.0909 and 150.0672 were similar to the product ions
of the parent compound. The fragment ion at m/z 289.1912 was the
result of m/z 303.2065 loss CH2 (14.0153Da), which suggested that
the A and B rings of verapamil had not undergone O‐demethylation.
These observations provided unambiguous evidence that M12‐5 was
verapamil with loss of CH2, owing to the N‐demethylation of verapa-
mil, and it agreed with MS fragment information.3.3 | Separation and analysis of isomers
In the present study, the UNIFI platform applied to data from ultra‐
performance liquid chromatography coupled with quadrupole time‐of‐
flight mass spectrometry (UPLC–MSE–QTOF) was used to isolate and
identify the verapamil metabolite isomers. Fifteen group isomers were
discovered, including metabolites M1, M2, M4, M5, M6, M8, M9, M10,
M11, M12, M14, M17, M18, M19 and M22. To illustrate the specific
operating principle, four representative isomer samples were listed. Four
chromatographic peaks could be detected with the molecular
TABLE 1 Summary of verapamil metabolites in plasma, urine and faeces
Name Metabolic pathway Formula [M + H]+
Retention
time (min)
Mass
error
(mDa)
Reaponse
Plasma Urine Feces
0.25 h 1.5 h 12 h
0–
12 h 0–12 h
12–
24 h
M0 Parent C27H38N2O4 455.290 15.01 0.00 +++ +++ ++ +++ + n.d.
M1‐1 N‐Dealkylation + N‐demethylation + O‐
demethylation (B ring) + glucuronide
conjugation
C21H30N2O8 439.208 5.10 0.00 + ++ ++ ++ n.d. n.d.
M1‐2 N‐Dealkylation + 2 × demethylation + glucuronide
conjugation
C21H30N2O8 439.207 5.20 −0.40 + ++ ++ ++ n.d. n.d.
M1‐3 N‐dealkylation + N‐demethylation + O‐
demethylation (B ring) + glucuronide
conjugation
C21H30N2O8 439.207 5.72 −0.50 n.d. + + + n.d. n.d.
M1‐4 N‐Dealkylation + 2 × demethylation + glucuronide
conjugation
C21H30N2O8 439.208 5.97 0.10 n.d. + n.d. ++ n.d. n.d.
M2‐1 N‐Dealkylation + O‐demethylation (B ring)
+ glucuronide conjugation
C22H32N2O8 453.223 5.32 −0.30 +++ +++ +++ +++ n.d. n.d.
M2‐2 N‐Dealkylation + O‐demethylation (B ring)
+ glucuronide conjugation
C22H32N2O8 453.223 5.41 −0.10 ++ +++ ++ +++ +++ n.d.
M2‐3 N‐Dealkylation + O‐demethylation (B ring)
+ glucuronide conjugation
C22H32N2O8 453.223 5.91 −0.50 + ++ + ++ n.d. n.d.
M2‐4 N‐Dealkylation + O‐demethylation (B ring)
+ glucuronide conjugation
C22H32N2O8 453.223 6.17 −0.30 + ++ + ++ n.d. n.d.
M3 Verapamil‐C17H24N2O2 (cleavage)–CH2–H2 C9H10O2 151.075 7.46 0.00 +++ +++ + +++ n.d. n.d.
M4–
1
N‐Dealkylation + O‐demethylation(B ring) C16H24N2O2 277.190 8.05 −0.60 + + + +++ +++ n.d.
M4–
2
N‐Dealkylation + O‐demethylation(B ring) C16H24N2O2 277.191 8.40 −0.60 + + + ++ +++ n.d.
M4–
3
N‐Dealkylation + N‐demethylation C16H24N2O2 277.191 9.74 −0.10 ++ +++ ++ +++ + n.d.
M5–
1
oxidation and demethylation to C17H26N2O2 area C26H36N2O5 457.270 9.07 0.20 n.d. n.d. n.d. 1792 917 n.d.
M5–
2
Oxidation + demethylation C26H36N2O5 457.270 9.29 −0.10 + + + n.d. n.d. n.d.
M5–
3
Oxidation and demethylation to C17H26N2O2 area C26H36N2O5 457.270 10.20 0.00 + n.d. n.d. + + n.d.
M5–
4
Oxidation + demethylation C26H36N2O5 457.270 11.50 −0.10 + + n.d. n.d. + n.d.
M5–
5
Oxidation and demethylation to C17H26N2O2 area C26H36N2O5 457.269 12.34 −0.40 ++ ++ ++ n.d. n.d. n.d.
M5–
6
Oxidation to A ring or carbon next to it + N‐
demethylation
C26H36N2O5 457.269 13.53 −0.30 ++ ++ + + ++ n.d.
M6‐1 2 × Demethylation to C17H26N2O2
area + glucuronide conjugation
C31H42N2O10 603.291 9.58 0.00 ++ ++ ++ ++ n.d. n.d.
M6‐2 2 × Demethylation + glucuronide conjugation C31H42N2O10 603.292 10.06 0.20 n.d. + n.d. n.d. n.d. n.d.
M6‐3 2 × Demethylation + glucuronide conjugation C31H42N2O10 603.293 10.34 1.30 n.d. + + n.d. n.d. n.d.
M6‐4 O‐demethylation (A ring) + N‐Demethylation +
glucuronide conjugation
C31H42N2O10 603.291 10.73 −0.20 +++ +++ +++ ++ n.d. n.d.
M6‐5 O‐Demethylation (A ring) + demethylation to
C17H26N2O2 + glucuronide conjugation
C31H42N2O10 603.291 11.33 0.00 + + + + n.d. n.d.
M7 N‐Dealkylation C17H26N2O2 291.207 10.03 −0.10 +++ +++ + +++ ++ n.d.
(Continues)
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TABLE 1 (Continued)
Name Metabolic pathway Formula [M + H]+
Retention
time (min)
Mass
error
(mDa)
Reaponse
Plasma Urine Feces
0.25 h 1.5 h 12 h
0–
12 h 0–12 h
12–
24 h
M8‐1 Oxidation to C17H26N2O2 area C27H38N2O5 471.285 10.44 −0.20 + + n.d. + n.d. n.d.
M8‐2 Oxidation C27H38N2O5 471.285 12.54 −0.10 n.d. n.d. n.d. n.d. ++ n.d.
M8‐3 Oxidation to C17H26N2O2 area C27H38N2O5 471.285 12.76 0.00 ++ ++ ++ n.d. n.d. n.d.
M8‐4 Oxidation to A ring or carbon next to it C27H38N2O5 471.285 13.80 −0.40 ++ ++ + n.d. n.d. n.d.
M8‐5 Oxidation C27H38N2O5 471.285 13.92 −0.20 ++ ++ + + n.d. n.d.
M8‐6 Oxidation C27H38N2O5 471.286 15.39 0.30 + + + n.d. n.d. n.d.
M9‐1 Demethylation + glucuronide conjugation C32H44N2O10 617.308 9.74 0.60 + + + + n.d. n.d.
M9‐2 O‐Demethylation (A ring) + glucuronide
conjugation
C32H44N2O10 617.307 10.58 −0.20 ++ ++ ++ + n.d. n.d.
M9‐3 Demethylation + glucuronide conjugation C32H44N2O10 617.307 11.48 0.40 + + n.d. n.d. n.d. n.d.
M10‐
1
O‐Demethylation (B ring) + 2 × demethylation (A
ring)
C24H32N2O4 413.243 10.39 −0.40 n.d. n.d. n.d. n.d. 154193 n.d.
M10‐
2
2 × Demethylation (A ring) + O‐demethylation (B
ring)
C24H32N2O4 413.243 10.67 −0.40 n.d. n.d. n.d. n.d. ++ n.d.
M10‐
3
O‐Demethylation (A ring) + 2 × demethylation to
C17H26N2O2 area
C24H32N2O4 413.243 11.35 −0.50 n.d. n.d. n.d. n.d. ++ n.d.
M10‐
4
O‐Demethylation (A ring) + 2 × demethylation to
C17H26N2O2 area
C24H32N2O4 413.243 11.66 −0.30 n.d. n.d. n.d. n.d. + n.d.
M10‐
5
2 × Demethylation (A ring) + N‐demethylation C24H32N2O4 413.243 12.09 0.00 n.d. n.d. n.d. n.d. +++ n.d.
M11‐
1
O‐Demethylation (A ring) + demethylation to
C17H26N2O2 area
C25H34N2O4 427.259 11.57 −0.60 n.d. n.d. n.d. n.d. + n.d.
M11‐
2
2 × Demethylation (A ring) C25H34N2O4 427.259 12.25 0.00 n.d. n.d. n.d. n.d. +++ n.d.
M11‐
3
2 × Demethylation to C17H26N2O2 area C25H34N2O4 427.258 12.80 −0.80 + + + + ++ n.d.
M11‐
4
2 × Demethylation to C17H26N2O2 area C25H34N2O4 427.259 13.11 −0.20 + + + n.d. n.d. n.d.
M11‐
5
O‐Demethylation (A ring) + N‐demethylation C25H34N2O4 427.259 13.24 −0.20 + + + ++ +++ n.d.
M11‐
6
O‐Demethylation (A ring) + demethylation to
C17H26N2O2 area
C25H34N2O4 427.259 13.62 −0.10 n.d. n.d. n.d. n.d. + n.d.
M12‐
1
O‐Demethylation (B ring) C26H36N2O4 441.274 13.11 −0.40 n.d. n.d. n.d. + ++ n.d.
M12‐
2
O‐demethylation (B ring) C26H36N2O4 441.274 13.42 −0.30 ++ ++ ++ n.d. n.d. n.d.
M12‐
3
O‐demethylation (A ring) C26H36N2O4 441.275 13.44 −0.30 n.d. n.d. n.d. + +++ n.d.
M12‐
4
O‐demethylation (A ring) C26H36N2O4 441.275 13.90 −0.30 n.d. n.d. n.d. n.d. ++ n.d.
M12‐
5
N‐Demethylation C26H36N2O4 441.274 14.66 −0.40 +++ +++ +++ +++ ++ n.d.
M13 verapamil‐C11H15NO2(cleavage) + O + 2 × (−H2) C16H19NO3 274.144 16.50 −0.20 +++ ++ ++ n.d. + n.d.
M14‐
1
N‐Dealkylation + 2 × demethylation (B ring) C15H22N2O2 263.175 6.31 −0.30 n.d. n.d. n.d. n.d. ++ n.d.
C15H22N2O2 263.175 7.76 −0.20 n.d. n.d. n.d. + ++ n.d.
(Continues)
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TABLE 1 (Continued)
Name Metabolic pathway Formula [M + H]+
Retention
time (min)
Mass
error
(mDa)
Reaponse
Plasma Urine Feces
0.25 h 1.5 h 12 h
0–
12 h 0–12 h
12–
24 h
M14‐
2
N‐Dealkylation + N‐demethylation + O‐
demethylation (B ring)
M14‐
3
N‐Dealkylation + 2 × demethylation C15H22N2O2 263.175 8.13 −0.40 n.d. n.d. n.d. + ++ n.d.
M15 Oxidation to A ring or carbon next to it + N‐
demethylation + O‐demethylation (B ring)
C25H34N2O5 443.255 11.71 1.00 n.d. n.d. n.d. + ++ n.d.
M16 5 × Demethylation C22H28N2O4 385.212 8.44 −0.10 n.d. n.d. n.d. n.d. + n.d.
M17‐
1
2 × Demethylation (A ring) + 2 × demethylation to
C17H26N2O2 area
C23H30N2O4 399.228 8.60 0.40 n.d. n.d. n.d. n.d. + n.d.
M17‐
2
O‐Demethylation (B ring) + N‐demethylation +
2 × demethylation (A ring)
C23H30N2O4 399.228 10.21 −0.30 n.d. n.d. n.d. n.d. +++ n.d.
M17‐
3
O‐Demethylation (B ring) + N‐demethylation +
2 × demethylation (A ring)
C23H30N2O4 399.227 10.51 −0.40 n.d. n.d. n.d. n.d. ++ n.d.
M18‐
1
3 × Demethylation‐dehydrogenation C24H30N2O4 411.227 9.41 −0.40 n.d. n.d. n.d. n.d. + n.d.
M18‐
2
3 × Demethylation‐dehydrogenation C24H30N2O4 411.227 9.55 −0.50 n.d. n.d. n.d. n.d. + n.d.
M18‐
3
O‐demethylation (B ring) + N‐demethylation + O‐
demethylation (A ring) + dehydrogenation
C24H30N2O4 411.228 10.06 −0.10 n.d. n.d. n.d. n.d. +++ n.d.
M18‐
4
O‐Demethylation (B ring) + N‐demethylation + O‐
demethylation (A ring) + dehydrogenation
C24H30N2O4 411.228 10.79 −0.30 n.d. n.d. n.d. n.d. ++ n.d.
M18‐
5
3 × Demethylation‐dehydrogenation C24H30N2O4 411.227 11.10 −0.60 n.d. n.d. n.d. n.d. + n.d.
M19‐
1
2 × Demethylation to C11H17NO2 area
+ dehydrogenation
C25H32N2O4 425.243 11.20 −0.30 n.d. n.d. n.d. n.d. ++ n.d.
M19‐
2
2 × Demethylation to C11H17NO2 area
+ dehydrogenation
C25H32N2O4 425.243 11.42 −0.20 n.d. n.d. n.d. n.d. ++ n.d.
M19‐
3
O‐Demethylation (A ring) + N‐demethylation +
dehydrogenation
C25H32N2O4 425.244 11.99 0.10 n.d. n.d. n.d. n.d. +++ n.d.
M19‐
4
O‐Demethylation (A ring) + N‐demethylation +
dehydrogenation
C25H32N2O4 425.243 12.76 −0.20 n.d. n.d. n.d. n.d. +++ n.d.
M20 3 × Oxidation C27H38N2O7 503.275 11.52 −0.20 n.d. n.d. n.d. n.d. + n.d.
M21 Oxidation + demethylation (to A ring or C next to
it) + sulfation
C26H36N2O8S 537.226 12.95 −0.10 n.d. n.d. n.d. n.d. + n.d.
M22‐
1
Demethylation + dehydrogenation C26H34N2O4 439.259 12.34 0.00 n.d. n.d. n.d. n.d. ++ n.d.
M22‐
2
Demethylation + dehydrogenation C26H34N2O4 439.259 12.50 0.20 n.d. n.d. n.d. n.d. + n.d.
Note: n.d., not detected; +, peak area < 103; ++, peak area 105; +++, peak area 106.
ZHU ET AL. 7 of 11composition C22H32N2O8 (M2‐1, M2‐2, M2‐3 and M2‐4, shown in
Figure 4), which eluted at 5.32, 5.41, 5.91 and 6.17min, respectively,
with the same [M + H]+ ions at m/z 453.2228 (C22H32N2O8, error
− 0.3 mDa). The fragment ions at m/z 277.1910, 246.1487,
234.1362 and 246.1487 were derived from the O‐demethylation (B
ring) of m/z 260.1645 by loss of CH2 (14.0158Da); m/z 234.1362
was 43.0548Da less than m/z 277.1910, which was derived from
N‐dealkylation. In addition, the fragment ion m/z 453.2331 was176.0421 Da (higher than m/z 277.1910), suggesting that it was a glu-
curonide conjunction. Metabolite M2‐1 was, therefore, assumed to
have undergone N‐dealkylation, O‐demethylation (B ring) and glucuro-
nide conjugation of the verapamil prototype, which agreed with MS
fragment information. Further analysis indicated that the four metab-
olites were isomers, because they exhibited the same protonated ion
at m/z 277.1910 and had characteristic neutral losses of
176.0421Da. Their different retention times on the UPLC system
FIGURE 3 MS2 fragmentation pattern of verapamil. Arrows in the molecular structure of the drug demonstrate the resulting cationic species
upon collision induced dissociation and detailed fragmentation pathway of verapamil based on Xevo G2‐XS QTOF MS2 and MS3 experiments
FIGURE 4 Based on UPLC separation technology and UNIFI software data processing, the separation and identification of multiple pairs of
verapamil metabolites isomers were obtained. (a), (b), (c), (d) are the four pairs isomers of verapamil glucuronic acid conjugates
8 of 11 ZHU ET AL.indicated that isomerization took place in the conjugation reaction in
different positions.
3.4 | Metabolites M3 and M13
Metabolites M3 and M13 had not previously been reported in the lit-
erature, and their structures were elucidated. Metabolite M3 eluted at7.46min and had its [M + H]+ ion at m/z 151.0753 (C9H10O2, error 0
mDa). M3 could be detected in plasma and urine. Metabolite M13 was
eluted at 16.50min, with [M + H]+ at m/z 274.1435 (C16H19NO3,
error −0.2 mDa). In the ESI–MS2 spectra of M13, product ions at m/
z 247.1435, m/z 231.0881 and m/z 189.0782 were observed (shown
in Supporting Figure S2), providing evidence for demethylation and
oxidation occurred on N.
FIGURE 5 The possible metabolic pathway of verapamil
ZHU ET AL. 9 of 113.5 | Summary of the metabolic pathway of
verapamil
In this study, 71 metabolites (including the prototype compound) with
different structures were observed and identified in rats following oral
administration of verapamil. The proposed metabolic pathway of
verapamil in rats is presented in Figure 5. Both phase I and II reactions
were involved in verapamil metabolism. For instance, 37 verapamil
metabolites were detected in rat plasma samples, including 21 phase
I metabolites and 16 phase II metabolites. Thirty‐one metabolites of
verapamil were found in rat urine. Of these, 18 metabolites were
phase I metabolites, and 13 were phase II metabolites. In rat faeces,
45 verapamil metabolites were detected; 44 were phase I metabolites
and one was a phase II metabolite. The phase I metabolic pathway
consisted of N‐demethylation, N‐dealkylation, oxidation, dehydroge-
nation and hydroxylation. Products from this primary metabolism fur-
ther underwent glucuronidation and sulfation in phase. Verapamil
metabolism appears to include the following major pathways: verapa-
mil was first biotransformed into M3, M7 (dealkylation product), M8
(oxidation product), M11 (di‐demethylation product), M12 (demethyl-
ation product), M13 and so on. Subsequently, a series of bioreactions
occurred, including demethylation (M4, M10), oxidation (M5), glucuro-
nide conjugation (M6, M9) and sulfation (M21), as well as their compli-
cated biotransformation products. For instance, M17 was identified as
arising from the demethylation of M10‐5. M15 was identified as a
demethylation product of M5‐6. M11 was converted into M19 by
dehydrogenation and then was biotransformed into M18. M4 was fur-
ther converted into M14 by demethylation, and then conjugation glu-
curonide reactions occurred on M14 to produce its conjugation
product M1. Other metabolites were generated by verapamil,undergoing multiple reactions. It is notable that the phase II metabo-
lites in rat faeces consist only of a sulfation product, M21.4 | CONCLUSIONS
UNIFI integrates a number of data‐mining tools for drug metabolite
detection and can perform automated spectral interpretation for the
structural determination of metabolites using an HRMS‐based
approach. Among the verapamil metabolites identified, 54 metabolites
were phase I and 17 were phase II, such as glucuronide and sulfate
conjugates. Some of the metabolites detected have not been reported
in the literature and are currently undergoing structural analysis. The
major metabolic pathways in rats are N‐ and O‐demethylation and N‐
dealkylation. Products from this primary metabolism undergo further
glucuronidation and sulfation. In addition, multiple minor metabolites
from hydroxylation were detected.
The combination of UPLC–MSE data acquisition technology and
the integrated data‐processing functions of the UNIFI platform pro-
vides several advances when finding and identifying metabolites. First,
MDF incorporated with the intelligent dealkylation function is capable
of rapidly detecting small metabolites from dealkylation, with no false
negative results. Second, the Binary Compare function allows compar-
ison of ions between experimental and control samples so that metab-
olites can be easily identified. Third, the MassFragment™ function
enables automated interpretation of the mass spectra of unknown
metabolites. Finally, the workflow of generic data acquisition, com-
bined with data‐mining and data interpretation functions, is well
suited for high‐throughput screening and analysis of reactive metabo-
lites and metabolic soft‐spots in a drug discovery setting.
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